… and actionable manner, today reported financial results for the first quarter ended … Pharmaceuticals, Turning Point Therapeutics, Novartis, Gilead, and McKinsey & Company Anticipated … in 2025 First Quarter 2025 Financial Results Net loss for the quarter …

… innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended … and Executive Vice President of Gilead Sciences, Inc. He currently serves on … and Chief Executive Officer. 2025 Financial Results As of March 31, 2025 …

… , today reported first quarter 2025 financial results and continued portfolio progress. “The … late 2025. First Quarter 2025 Financial Results Cash Position: Cash and cash … roles of increasing seniority at Gilead Sciences, and was an attorney at …

… serious viral diseases, today reported financial results and recent updates for the … ABI-1179 was contributed by Gilead Sciences, Inc. (Gilead) under the collaboration between … benefits of its collaboration with Gilead Sciences, Inc., including all financial …

… , today reported business highlights and financial results for the first quarter ended … is partnered with Kite, a Gilead Company. Appointed Andrew Galligan and …

… , and autoimmune disease, today reported financial results for the three months ended … at leading pharmaceutical organizations, including Gilead, Daiichi Sankyo and BMS, will … 10% on future product sales. Financial Results for the Three Months Ended …

… business updates and reported financial results for the first quarter … license agreement with Gilead Sciences, Inc. (Gilead) related to Xilio … exclusive license agreement with Gilead Sciences, Inc. for Xilio … agreements with AbbVie and Gilead; the ability to …

… Incorporated (Nasdaq: LGND) today reported financial results for the three months ended … strategy.” First Quarter 2025 Financial Results Total revenues and other income … including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more …

… Triclonics® and ADClonics®), today announced financial results for the first quarter and … preclinical development. Gilead Sciences In March 2024, Merus and Gilead Sciences announced a … program from the collaboration, Gilead will be responsible for additional …

… patients with cancer, today reported financial results for the first quarter ended … are investigational molecules, and neither Gilead nor Arcus has received approval … our portfolio. Under this collaboration, Gilead obtained time-limited exclusive option …